Page last updated: 2024-09-04

moxifloxacin and Adenoma, Prostatic

moxifloxacin has been researched along with Adenoma, Prostatic in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Armstrong, P; Borer, J	1
Kees, F; Lunz, JC; Naber, KG; Wagenlehner, FM; Wieland, W	1

Trials

1 trial(s) available for moxifloxacin and Adenoma, Prostatic

Article	Year
Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate. Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:5 Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Biological Availability; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Prostate; Prostatic Hyperplasia; Prostatitis; Quinolines; Transurethral Resection of Prostate	2006

Article

Year

Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate.

Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:5

Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Biological Availability; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Prostate; Prostatic Hyperplasia; Prostatitis; Quinolines; Transurethral Resection of Prostate

2006

Other Studies

1 other study(ies) available for moxifloxacin and Adenoma, Prostatic

Article	Year
Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. Circulation, 2003, Jun-17, Volume: 107, Issue:23 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adolescent; Adult; Advisory Committees; Anti-Infective Agents; Aza Compounds; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Approval; Electrocardiography; Fluoroquinolones; Humans; Imidazoles; Impotence, Vasculogenic; Male; Middle Aged; Moxifloxacin; Phosphoric Diester Hydrolases; Piperazines; Prostatic Hyperplasia; Quinazolines; Quinolines; Risk Assessment; Sulfones; Triazines; United States; United States Food and Drug Administration; Vardenafil Dihydrochloride	2003

Article

Year

Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.

Circulation, 2003, Jun-17, Volume: 107, Issue:23

Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adolescent; Adult; Advisory Committees; Anti-Infective Agents; Aza Compounds; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Approval; Electrocardiography; Fluoroquinolones; Humans; Imidazoles; Impotence, Vasculogenic; Male; Middle Aged; Moxifloxacin; Phosphoric Diester Hydrolases; Piperazines; Prostatic Hyperplasia; Quinazolines; Quinolines; Risk Assessment; Sulfones; Triazines; United States; United States Food and Drug Administration; Vardenafil Dihydrochloride

2003